Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib versus investigator's choice therapy in relapsed or refractory chronic lymphocytic leukemia
2023-509359-15-00Phase 3Authorised
- Sponsor
- Acerta Pharma
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by Acerta Pharma. Primary endpoint: Progression-free survival. Planned start Mar 2017; status: authorised.
02
Drugs
acalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-509359-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509359-15-00.